<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PARICALCITOL- paricalcitol injection, solution </strong><br>Hospira, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PARICALCITOL INJECTION safely and effectively. See full prescribing information for PARICALCITOL INJECTION.<br>PARICALCITOL INJECTION, for intravenous use<br>Initial U.S. Approval: 1998 </div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Paricalcitol Injection is an active vitamin D<span class="Sub">2</span> analog indicated for the prevention and treatment of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> associated with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> Stage 5. (<a href="#dd06ed48-099d-4375-a6cc-cb57605f25d3">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>The recommended starting dose is 0.04 mcg/kg to 0.1 mcg/kg (2.8 – 7 mcg)</dd>
<dt>•</dt>
<dd>Administer Paricalcitol Injection as a bolus through a hemodialysis vascular access port at any time during dialysis.  Dosing should not occur more frequently than every other day.</dd>
<dt>•</dt>
<dd>Do not inject Paricalcitol Injection directly into a vein.</dd>
<dt>•</dt>
<dd>Paricalcitol Injection dose should be individualized. If a satisfactory PTH lowering response is not observed with the initial dose, the dose may be increased by 2 to 4 mcg at 2- to 4- week intervals based on parathyroid hormone (PTH) levels. (<a href="#ad5c39ef-7b0c-4324-b63d-b58783cb4ca7">2</a>)</dd>
</dl>
<table width="100%">
<caption><span>Suggested Dosage Adjustment</span></caption>
<col width="67%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center"><p class="Highlighta"><span class="Bold">PTH Level at Follow-up Visit</span> </p></td>
<td class="Botrule Toprule" align="center"><p class="Highlighta"><span class="Bold">Dosage Adjustment</span> </p></td>
</tr>
<tr>
<td><p class="Highlighta">Above target and PTH increased </p></td>
<td align="center" valign="middle"><p class="Highlighta">Increase </p></td>
</tr>
<tr>
<td><p class="Highlighta">Above target and PTH decreased by less than 30% </p></td>
<td align="center" valign="middle"><p class="Highlighta">Increase </p></td>
</tr>
<tr>
<td><p class="Highlighta">Above target and PTH decreased by 30 to 60% </p></td>
<td align="center" valign="middle"><p class="Highlighta">No Change </p></td>
</tr>
<tr>
<td><p class="Highlighta">Above target and PTH decreased by more than 60% </p></td>
<td align="center" valign="middle"><p class="Highlighta">Decrease </p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="Highlighta">At target and PTH stable </p></td>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">No Change </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Paricalcitol Injection is available as a multi-dose vial in the following presentations (<a href="#ef5eac8e-ef91-49ce-81f4-9904c6f6e762">3</a>): 2 mcg per mL, 5 mcg per mL, 10 mcg per 2 mL (5 mcg per mL) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Evidence of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, vitamin D toxicity or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<a href="#f9e85617-503c-4f02-9023-948c63153462">4</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></span>: The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or metabolically inactive or active forms of vitamin D.  Monitor serum calcium when using Paricalcitol Injection and adjust dose accordingly. (<a href="#feae94e0-9062-4479-821a-28e1e05a5847">5.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digitalis Toxicity</span></span>: <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> increases the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. In patients using Paricalcitol Injection concomitantly with digitalis compounds, monitor both serum calcium and patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> and increase frequency of monitoring when initiating or adjusting the dose of Paricalcitol Injection. (<a href="#d42a2eba-b1c6-4b39-8619-e874a7993c79">5.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Underline">Risk of Increased Paricalcitol Levels With Concomitant Use of Strong CYP3A Inhibitors</span>: Use of Paricalcitol Injection with strong CYP3A inhibitors increases the concentration of paricalcitol in the blood. In patients on Paricalcitol Injection who are initiating or discontinuing drugs known to be strong CYP3A inhibitors, monitor serum calcium and PTH more frequently and adjust Paricalcitol Injection dose as required. (<a href="#d5c9b9e7-2dd9-427a-9dfa-3de89cfdc8b1">5.3</a>)  </dd>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4126449" conceptname="Adynamic bone disease">Adynamic Bone Disease</span></span>: May develop if PTH levels are suppressed to abnormally low levels. Monitor PTH levels and adjust Paricalcitol Injection accordingly. (<a href="#ee5df371-76a0-46c5-97f8-d9e67b7db65b">5.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (greater than 5% and more frequent than placebo) include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<a href="#ID_148d1075-ccca-4305-922f-aaef9985503f">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Co-administration with strong CYP3A inhibitors (e.g. ketoconazole) increases paricalcitol blood levels. See <a href="#a2e9dd73-077c-4121-acab-c6935a309fc7">WARNINGS AND PRECAUTIONS</a> (<a href="#d5c9b9e7-2dd9-427a-9dfa-3de89cfdc8b1">5.3</a>, <a href="#a43da245-2080-41a0-ac74-46a22016020d">7.1</a>).  </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Underline">Pregnancy:</span> Use during pregnancy only if the potential benefit justifies the potential risk (<a href="#af8c3d96-b218-44f1-9d0e-e2cdd819aba8">8.1</a>).</dd>
<dt>•</dt>
<dd>
<span class="Underline">Nursing Mothers</span>: A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (<a href="#b61c02a3-324e-4786-8a85-a1c1a28fc158">8.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digitalis Toxicity</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Risk of Increased Paricalcitol Levels With Concomitant Use of Strong CYP3A Inhibitors  </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4126449" conceptname="Adynamic bone disease">Adynamic Bone Disease</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong CYP3A Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Treatment of Overdosage and <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="dd06ed48-099d-4375-a6cc-cb57605f25d3"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Paricalcitol Injection is an active vitamin D<span class="Sub">2</span> analog indicated for the prevention and treatment of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> associated with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD) Stage 5.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ad5c39ef-7b0c-4324-b63d-b58783cb4ca7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous use through hemodialysis vascular access port only.</span></p>
<p>The recommended starting dose of Paricalcitol Injection is 0.04 mcg/kg to 0.1 mcg/kg (2.8 – 7 mcg) administered through a hemodialysis vascular access port as a bolus dose at any time during dialysis. Dosing should not occur more frequently than every other day. The drug product should not be injected directly into a vein. Dosage should be individualized. If a satisfactory parathyroid hormone (PTH) lowering response is not observed using the recommended starting dose, the dose may be increased by 2 to 4 mcg every 2 to 4 weeks based on PTH levels (refer to <a href="#_Ref402346426">Table 1</a>).</p>
<a name="_Ref402346426"></a><table cellpadding="0.75pt" width="100%">
<caption><span>Table 1: Suggested Dosage Adjustment</span></caption>
<col width="54%">
<col width="46%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">PTH Level at Follow-up Visit</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dosage Adjustment</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Above target and PTH increased</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Increase</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Above target and PTH decreased by less than 30%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Increase</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Above target and PTH decreased by 30 to 60%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">No Change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Above target and PTH decreased by more than 60%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Decrease</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">At target and PTH stable</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">No Change</p></td>
</tr>
</tbody>
</table>
<p>When initiating Paricalcitol Injection or adjusting Paricalcitol Injection dose, measure serum calcium and phosphorus frequently (e.g., twice weekly) and PTH every 2 to 4 weeks. Once a maintenance dose has been established, serum calcium and phosphorus should be measured at least monthly and plasma PTH every 3 months.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ef5eac8e-ef91-49ce-81f4-9904c6f6e762"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Paricalcitol Injection is available as a multi-dose vial in the following presentations:</p>
<dl>
<dt>•</dt>
<dd>2 mcg per mL</dd>
<dt>•</dt>
<dd>5 mcg per mL</dd>
<dt>•</dt>
<dd>10 mcg per 2 mL (5 mcg per mL) </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="f9e85617-503c-4f02-9023-948c63153462"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Paricalcitol Injection is contraindicated in patients with evidence of:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> [<span class="Italics">see <a href="#feae94e0-9062-4479-821a-28e1e05a5847">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>•</dt>
<dd>Vitamin D toxicity [<span class="Italics">see <a href="#feae94e0-9062-4479-821a-28e1e05a5847">Warnings and Precautions (5.1)</a></span>] or</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to paricalcitol or any inactive ingredient in this product [<span class="Italics">see <a href="#ID_9f81570a-dc44-4baa-b1dc-bf1c9a3f5f78">Adverse reactions (6.2)</a></span>]</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="a2e9dd73-077c-4121-acab-c6935a309fc7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="feae94e0-9062-4479-821a-28e1e05a5847"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may occur during Paricalcitol Injection treatment and may be exacerbated by concomitant administration of high doses of calcium containing preparations, thiazide diuretics, or vitamin D (i.e., all forms). Acute <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may exacerbate tendencies for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and may potentiate the effect of digitalis on the heart. Chronic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> can lead to generalized <span class="product-label-link" type="condition" conceptid="4030365" conceptname="Vascular calcification">vascular calcification</span> and other soft-tissue calcification. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may be so severe as to require emergency attention. </p>
<p>High intake of calcium and phosphate concomitantly with vitamin D compounds may lead to <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, and <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>. Prevention of such adverse reactions requires frequent serum calcium monitoring and careful Paricalcitol Injection dose adjustments. </p>
<p>Concomitant use with other active vitamin D analogues should be avoided during Paricalcitol Injection treatment to prevent <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>. </p>
<p>Patients also should be informed about the symptoms of elevated calcium, which include feeling tired, <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">difficulty thinking</span> clearly, loss of appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span>, increased urination and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="d42a2eba-b1c6-4b39-8619-e874a7993c79"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digitalis Toxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> of any cause increases the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.  In patients using Paricalcitol Injection concomitantly with digitalis compounds, monitor both serum calcium and patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> and increase frequency of monitoring when initiating or adjusting the dose of Paricalcitol Injection [<span class="Italics">see <a href="#ad5c39ef-7b0c-4324-b63d-b58783cb4ca7">Dosage and Administration (2)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="d5c9b9e7-2dd9-427a-9dfa-3de89cfdc8b1"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Risk of Increased Paricalcitol Levels With Concomitant Use of Strong CYP3A Inhibitors  </h2>
<p class="First">Concomitant use of Paricalcitol Injection with strong CYP3A inhibitors will increase the levels of paricalcitol in the blood. In patients on Paricalcitol Injection who are initiating or discontinuing therapy with drugs known to be strong CYP3A inhibitors, monitor serum calcium and PTH more frequently and adjust Paricalcitol Injection dose as required [<span class="Italics">see <a href="#a43da245-2080-41a0-ac74-46a22016020d">Drug Interactions (7.1)</a>, <a href="#db9ce2bb-edc4-4294-9e95-f7071cae13a0">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ee5df371-76a0-46c5-97f8-d9e67b7db65b"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4126449" conceptname="Adynamic bone disease">Adynamic Bone Disease</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126449" conceptname="Adynamic bone disease">Adynamic bone disease</span> with subsequent increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> may develop if PTH levels are suppressed to abnormally low levels. Monitor PTH levels and adjust Paricalcitol Injection dose [<span class="Italics">see </span><span class="Italics"><a href="#ad5c39ef-7b0c-4324-b63d-b58783cb4ca7">Dosage and Administration (2)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="bc53fa85-37b6-46cf-99ea-1b5ea67362aa"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_148d1075-ccca-4305-922f-aaef9985503f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>Safety has been evaluated in clinical studies conducted with another paricalcitol injection product in 609 patients with CKD Stage 5. In four, placebo-controlled, double-blind, multicenter studies, discontinuation of therapy due to any adverse event occurred in 6.5% of 62 patients treated with paricalcitol injection (dosage titrated as tolerated, [<span class="Italics">see <a href="#db6cbf59-4b2f-477b-9360-27c9fc6cc3df">Clinical Studies (14)</a></span>]) and 2.0% of 51 patients treated with placebo for 1 to 3 months. Adverse reactions occurring with greater frequency in the paricalcitol group and at a frequency of 2% or greater are presented in the following table:</p>
<table cellpadding="0.75pt" width="100%">
<caption><span>Table 2: Adverse Reactions Occurring at a Rate* of 2% or Greater in CKD Stage 5 Patients In Four Placebo-Controlled Studies</span></caption>
<col width="57%">
<col width="22%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(n=51)</span></p>
<p><span class="Bold">%</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Paricalcitol Injection</span></p>
<p><span class="Bold">(n=62)</span></p>
<p><span class="Bold">%</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First">* A patient who reported the same medical term more than once was counted only once for that medical term.</p></td></tr>
</tbody>
</table>
<p>Specific laboratory parameters [i.e., changes in mean Calcium (Ca), Phosphorus (P), and Calcium Phosphorus product (Ca × P)] were followed in an open-label safety study conducted with another paricalcitol injection product for up to 13 months in duration in this patient population and results are shown below [<span class="Italics">see <a href="#db6cbf59-4b2f-477b-9360-27c9fc6cc3df">Clinical Studies (14)</a></span>].</p>
<p><span class="Bold">Other Adverse Reactions Associated with Paricalcitol Injection Use</span></p>
<p>The following adverse reactions, occurred in less than 2% of the paricalcitol-treated patients in the above mentioned double-blind, placebo-controlled clinical trials and in additional double-blind, active-controlled and open-label studies:</p>
<p><span class="Italics">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> </p>
<p><span class="Italics">Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="4011332" conceptname="Sensation of blocked ears">Ear discomfort</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">intestinal ischemia</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> </p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, condition aggravated, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="442120" conceptname="Injection site extravasation">injection site extravasation</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span> </p>
<p><span class="Italics">Laboratory Investigations and Vital Signs: </span>Increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span>, prolonged <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, irregular heart rate, decreased weight </p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> </p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">Joint stiffness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Italics">Neoplasms Benign, Malignant and Unspecified:</span> Breast cancer</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4309389" conceptname="Unresponsive">unresponsive to stimuli</span> </p>
<p><span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> </p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> </p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="315361" conceptname="Orthopnea">orthopnea</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> </p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9f81570a-dc44-4baa-b1dc-bf1c9a3f5f78"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of another paricalcitol injection product. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>) have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="cce09f17-5087-4f56-a8d5-90dc9cd97921"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="a43da245-2080-41a0-ac74-46a22016020d"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong CYP3A Inhibitors</h2>
<p class="First">Paricalcitol is partially metabolized by CYP3A. Paricalcitol blood levels will be increased when paricalcitol is co-administered with strong CYP3A inhibitors. If a patient initiates or discontinues therapy with a strong CYP3A inhibitor, monitor both PTH and serum calcium more frequently and adjust Paricalcitol Injection dose as required [<span class="Italics">see</span> <span class="Italics"><a href="#db9ce2bb-edc4-4294-9e95-f7071cae13a0">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="de4cf473-331d-4338-ac29-9777ff40d36f"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="af8c3d96-b218-44f1-9d0e-e2cdd819aba8"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Underline">Pregnancy Category C</span></span></p>
<p>Paricalcitol has been shown to cause minimal decreases in fetal viability (5%) when administered daily to rabbits at a dose 0.5 times the 0.24 mcg/kg human dose (based on surface area, mg/m<span class="Sup">2</span>) and when administered to rats at a dose 2 times the 0.24 mcg/kg human dose (based on plasma levels of exposure). At the highest dose tested (20 mcg/kg 3 times per week in rats, 13 times the 0.24 mcg/kg human dose based on surface area), there was a significant increase of the mortality of newborn rats at doses that were maternally toxic (<span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>). No other effects on offspring development were observed. Paricalcitol was not teratogenic at the doses tested.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Paricalcitol Injection should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="b61c02a3-324e-4786-8a85-a1c1a28fc158"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies in rats have shown that paricalcitol is present in the milk. It is not known whether paricalcitol is excreted in human milk. In the nursing patient, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="d05570e4-b9f6-4f20-aab1-f9fab5709bcb"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of paricalcitol injection were examined with another paricalcitol injection product in a 12-week randomized, double-blind, placebo-controlled study of 29 pediatric patients, aged  5-19 years, with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis and nearly all had received some form of vitamin D prior to the study. Seventy-six percent of the patients were male, 52% were Caucasian and 45% were African-American. The initial dose of paricalcitol injection was 0.04 mcg/kg 3 times per week based on baseline iPTH level of less than 500 pg/mL, or 0.08 mcg/kg 3 times a week, based on baseline iPTH level of ≥ 500 pg/mL, respectively. The dose of paricalcitol injection was adjusted in 0.04 mcg/kg increments based on the levels of serum iPTH, calcium and Ca x P. The mean baseline levels of iPTH were 841 pg/mL for the 15 paricalcitol injection treated patients and 740 pg/mL for the 14 placebo-treated subjects. The mean dose of paricalcitol injection administered was 4.6 mcg (range: 0.8 mcg-9.6 mcg). Ten of the 15 (67%) paricalcitol injection-treated patients and 2 of the 14 (14%) placebo-treated patients completed the trial. Ten of the placebo patients (71%) were discontinued due to excessive elevations in iPTH levels as defined by 2 consecutive iPTH levels &gt; 700 pg/mL and greater than baseline after 4 weeks of treatment.</p>
<p>In the primary efficacy analysis, 9 of 15 (60%) subjects in the paricalcitol injection group had 2 consecutive 30% decreases from baseline iPTH compared with 3 of 14 (21%) patients in the placebo group (95% CI for the difference between groups -1%, 63%). Twenty-three percent of paricalcitol injection vs. 31% of placebo patients had at least one serum calcium level &gt; 10.3 mg/dL and 40% vs. 14% of paricalcitol injection vs. placebo subjects had at least one Ca x P ion product &gt; 72 (mg/dL)<span class="Sup">2</span>. The overall percentage of serum calcium measurements &gt; 10.3 mg/dL was 7% in the paricalcitol injection group and 7% in the placebo group; the overall percentage of patients with Ca x P product &gt; 72 (mg/dL)<span class="Sup">2</span> was 8% in the paricalcitol injection group and 7% in the placebo group. No subjects in either the paricalcitol injection group or placebo group developed <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (defined as at least one calcium value &gt; 11.2 mg/dL) during the study.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="a29cb34f-564f-4eea-81cd-922f2064013a"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of paricalcitol injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="e02307ab-6575-4039-bd42-ffe57df09f17"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of Paricalcitol Injection may lead to <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and over suppression of PTH resulting in <span class="product-label-link" type="condition" conceptid="4126449" conceptname="Adynamic bone disease">adynamic bone disease</span>. [<span class="Italics">see</span> <span class="Italics"><a href="#a2e9dd73-077c-4121-acab-c6935a309fc7">Warnings and Precautions</a> (<a href="#feae94e0-9062-4479-821a-28e1e05a5847">5.1</a>, <a href="#ee5df371-76a0-46c5-97f8-d9e67b7db65b">5.4</a>)</span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75d8b69b-ece0-441b-b4a1-0d20411176c9"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Treatment of Overdosage and <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">The treatment of acute overdosage should consist of supportive measures, discontinuation of drug administration and supplemental calcium, institution of a low calcium diet. Serum calcium levels should be measured until normocalcemia ensues. When serum calcium levels have returned to within normal limits, Paricalcitol Injection may be reinitiated at a lower dose.</p>
<p>Paricalcitol is not significantly removed by dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a93951f2-4859-47c1-babf-003e74058226"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Paricalcitol, USP, the active ingredient in Paricalcitol Injection, is a synthetically manufactured active vitamin D<span class="Sub">2</span> analog. It is a white powder chemically designated as 19-nor-1α,3β,25-trihydroxy-9,10-secoergosta-5(Z),7(E),22(E)-triene and has the following structural formula:</p>
<div class="Figure">
<a name="id1315913815"></a><img alt="Paricalcitol Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca&amp;name=image-01.jpg">
</div>
<p>Paricalcitol Injection is available as a sterile, clear, colorless, aqueous solution for intravenous injection. Each mL contains paricalcitol, 2 mcg or 5 mcg  and the following inactive ingredients: alcohol 40% (v/v) and propylene glycol 10% (v/v) in water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="c23e95f9-5326-4457-82eb-e53ca0a7f28b"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="f8d5e70d-de59-4258-b41b-438659354dfa"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Preclinical and <span class="Italics">in vitro</span> studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="db9ce2bb-edc4-4294-9e95-f7071cae13a0"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Within two hours after administering paricalcitol intravenous doses ranging from 0.04 to 0.24 mcg/kg, concentrations of paricalcitol decreased rapidly; thereafter, concentrations of paricalcitol declined log-linearly. No accumulation of paricalcitol was observed with three times a week dosing.</p>
<p><span class="Underline">Distribution</span>: Paricalcitol is extensively bound to plasma proteins (≥ 99.8%). In healthy subjects, the steady state volume of distribution is approximately 23.8 L. The mean apparent volume of distribution following a 0.24 mcg/kg dose of paricalcitol in CKD Stage 5 subjects requiring hemodialysis (HD) and peritoneal dialysis (PD) is between 31 and 35 L.</p>
<p><span class="Underline">Metabolism</span>: After intravenous administration of a 0.48 mcg/kg dose of <span class="Sup">3</span>H-paricalcitol, parent drug was extensively metabolized, with only about 2% of the dose eliminated unchanged in the feces and no parent drug found in the urine. Several metabolites were detected in both the urine and feces. Most of the systemic exposure was from the parent drug. Two minor metabolites, relative to paricalcitol, were detected in human plasma. One metabolite was identified as 24(R)-hydroxy paricalcitol, while the other metabolite was unidentified. The 24(R)-hydroxy paricalcitol is less active than paricalcitol in an <span class="Italics">in vivo</span> rat model of PTH suppression.</p>
<p><span class="Italics">In vitro</span> data suggest that paricalcitol is metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4. The identified metabolites include the product of 24(R)-hydroxylation (present at low levels in plasma), as well as 24,26- and 24,28-dihydroxylation and direct glucuronidation.</p>
<p><span class="Underline">Elimination</span>: Paricalcitol is excreted primarily by hepatobiliary excretion. Approximately 63% of a radioactive dose was recovered in the feces and 19% was recovered in the urine in healthy subjects. In healthy subjects, the mean elimination half-life of paricalcitol is about five to seven hours over the studied dose range of 0.04 to 0.16 mcg/kg. The pharmacokinetics of paricalcitol has been studied in CKD Stage 5 subjects requiring hemodialysis (HD) and peritoneal dialysis (PD). The mean elimination half-life of paricalcitol after administration of 0.24 mcg/kg paricalcitol intravenous bolus dose in CKD Stage 5 HD and PD patients is 13.9 and 15.4 hours, respectively (<a href="#_Ref402348558">Table 3</a>).</p>
<a name="_Ref402348558"></a><table cellpadding="0.75pt" width="100%">
<caption><span>Table 3: Mean ± SD Paricalcitol Pharmacokinetic Parameters in CKD Stage 5 Subjects Following Single 0.24 mcg/kg Intravenous Bolus Dose</span></caption>
<col width="34%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>harmonic mean ± pseudo standard deviation, HD: hemodialysis, PD: peritoneal dialysis. The degree of accumulation was consistent with the half-life and dosing frequency.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">CKD Stage 5 HD<br>n = 14</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">CKD Stage 5 PD<br>n = 8</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">C<span class="Sub">max</span> (ng/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.680 ± 0.511</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.832 ± 0.315</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">AUC<span class="Sub">0-∞</span> (ng•h/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14.51 ± 4.12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16.01 ± 5.98</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">β(1/h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.050 ± 0.023</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.045 ± 0.026</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">t1/2(h)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">13.9 ± 7.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15.4 ± 10.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">CL (L/h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.49 ± 0.60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.54 ± 0.95</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Vdβ (L)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">30.8 ± 7.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">34.9 ± 9.5</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Specific Populations</span></p>
<p><span class="Underline">Geriatric</span>: The pharmacokinetics of paricalcitol has not been investigated in geriatric patients greater than 65 years </p>
<p><span class="Underline">Pediatric</span>: The pharmacokinetics of paricalcitol has not been investigated in patients less than 18 years of age.</p>
<p><span class="Underline">Gender</span>: The pharmacokinetics of paricalcitol was gender independent.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: The disposition of intravenous paricalcitol (0.24 mcg/kg) was compared in patients with mild (n=5) and moderate (n=5) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (as indicated by the Child-Pugh method) and subjects with normal hepatic function (n=10). The pharmacokinetics of unbound paricalcitol were similar across the range of hepatic function evaluated in this study. No dosing adjustment is required in patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The influence of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of paricalcitol has not been evaluated.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: The pharmacokinetics of paricalcitol have been studied in CKD Stage 5 subjects requiring hemodialysis (HD) and peritoneal dialysis (PD). Hemodialysis procedure has essentially no effect on paricalcitol elimination. However, compared to healthy subjects, CKD Stage 5 subjects showed a decreased CL and increased half-life. </p>
<p><span class="Bold">Drug Interactions </span></p>
<p>An <span class="Italics">in vitro</span> study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A at concentrations up to 50 nM (21 ng/mL) (approximately 20-fold greater than that obtained after highest tested dose). In fresh primary cultured hepatocytes, the induction observed at paricalcitol concentrations up to 50 nM was less than two-fold for CYP2B6, CYP2C9 or CYP3A, where the positive controls rendered a six- to nineteen-fold induction. Hence, paricalcitol is not expected to inhibit or induce the clearance of drugs metabolized by these enzymes. </p>
<p>Drug interactions with Paricalcitol Injection have not been studied. The following studies have been performed with oral paricalcitol capsules.</p>
<p><span class="Underline">Omeprazole </span></p>
<p>The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between paricalcitol capsule (16 mcg) and omeprazole (40 mg; oral), a strong inhibitor of CYP2C19, was investigated in a single dose, crossover study in healthy subjects. The pharmacokinetics of paricalcitol were unaffected when omeprazole was administrated approximately 2 hours prior to the paricalcitol dose.</p>
<p><span class="Underline">Strong CYP3A Inhibitors</span></p>
<p>Ketoconazole </p>
<p>Although no data are available for the drug interaction between Paricalcitol Injection and ketoconazole, a strong inhibitor of CYP3A, the effect of multiple doses of ketoconazole administered as 200 mg BID for 5 days on the pharmacokinetics of paricalcitol capsule has been studied in healthy subjects. The C<span class="Sub">max</span> of paricalcitol was minimally affected, but AUC<span class="Sub">0-∞</span> approximately doubled in the presence of ketoconazole. The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone [<span class="Italics">see <a href="#a43da245-2080-41a0-ac74-46a22016020d">Drug Interactions (7.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="e11b4828-1302-4f17-9be5-73f36be57077"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="b083e1f1-057b-4419-88af-a2008588fa34"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104-week carcinogenicity study in CD-1 mice conducted with paricalcitol, an increased incidence of <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine leiomyoma</span> and leiomyosarcoma was observed at subcutaneous doses of 1, 3, 10 mcg/kg (2 to 15 times the AUC at a human dose of 14 mcg, equivalent to 0.24 mcg/kg based on AUC). The incidence rate of <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine leiomyoma</span> was significantly different than the control group at the highest dose of 10 mcg/kg.</p>
<p>In a 104-week carcinogenicity study in rats conducted with paricalcitol, there was an increased incidence of benign adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> at subcutaneous doses of 0.15, 0.5, 1.5 mcg/kg ( &lt; 1 to 7 times the exposure following a human dose of 14 mcg, equivalent to 0.24 mcg/kg based on AUC). The increased incidence of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in rats may be related to the alteration of calcium homeostasis by paricalcitol.</p>
<p>Paricalcitol did not exhibit genetic toxicity <span class="Italics">in vitro</span> with or without metabolic activation in the microbial mutagenesis assay (Ames Assay), mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagenesis assay (L5178Y), or a human lymphocyte cell chromosomal aberration assay. There was also no evidence of genetic toxicity in an <span class="Italics">in vivo</span> mouse micronucleus assay. Paricalcitol had no effect on fertility (male or female) in rats at intravenous doses up to 20 mcg/kg/dose [equivalent to 13 times the highest recommended human dose (0.24 mcg/kg) based on surface area, mg/m<span class="Sup">2</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="db6cbf59-4b2f-477b-9360-27c9fc6cc3df"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In three 12-week, placebo-controlled, phase 3 studies conducted with another paricalcitol injection product in patients with Stage 5 <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis, the dose of paricalcitol was started at 0.04 mcg/kg 3 times per week. The dose was increased by 0.04 mcg/kg every 2 weeks until intact parathyroid hormone (iPTH) levels were decreased at least 30% from baseline, or a fifth escalation brought the dose to 0.24 mcg/kg, or iPTH fell to less than 100 pg/mL, or the Ca x P product was greater than 75 within any 2 week period, or serum calcium became greater than 11.5 mg/dL at any time.</p>
<p>Patients treated with paricalcitol achieved a mean iPTH reduction of 30% within 6 weeks. In these studies, there was no significant difference in the incidence of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> or <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> between paricalcitol and placebo-treated patients. The results from these studies are as follows:</p>
<table cellpadding="0.75pt" width="100%">
<caption><span>Table 4: Mean Changes from Baseline to Final Evaluation in PTH, Alkaline Phosphatase, Phosphorus and Calcium x Phosphorus Product in CKD Stage 5 Patients in Three Placebo-Controlled, Phase 3 Studies </span></caption>
<col width="27%">
<col width="16%">
<col width="22%">
<col width="35%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Group<br>(No. of Pts.)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Baseline<br>Mean<br>(Range)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Mean (SE) Change From <br>Baseline to Final <br>Evaluation</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">PTH (pg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">paricalcitol<br>(n=40)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">783 (291–2076)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-379 (43.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">placebo<br>(n=38)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">745 (320 – 1671)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-69.6 (44.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Alkaline <br>Phosphatase <br>(U/L)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">paricalcitol<br>(n=31)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">150 (40 – 600)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-41.5 (10.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">placebo<br>(n=34)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">169 (56 – 911)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">+2.6 (10.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Phosphorus (mg/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">paricalcitol<br>(n=40)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5.8 (3.7 – 10.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">+0.47 (0.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">placebo<br>(n=38)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6.0 (2.8 – 8.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-0.47 (0.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Calcium x <br>Phosphorus <br>Product</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">paricalcitol<br>(n=40)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">54 (32 – 106)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">+7.9 (2.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">placebo<br>(n=38)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">54 (26 – 77)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-3.9 (2.3)</p></td>
</tr>
</tbody>
</table>
<p>A long-term, open-label safety study of 164 CKD Stage 5 patients conducted with another paricalcitol injection product (mean dose of 7.5 mcg three times per week), demonstrated that mean serum Ca, P, and Ca x P remained within clinically appropriate ranges with PTH reduction (mean decrease of 319 pg/mL at 13 months).</p>
<p><span class="Bold">Figure 1: Mean Values for Serum iPTH, Calcium and Phosphorus Over Time in CKD Stage 5 Patients in a Phase 3 Study</span></p>
<span class="Bold"><div class="Figure">
<a name="id575171713"></a><img alt="Figure 1: Mean Values for Serum iPTH, Calcium and Phosphorus Over Time in CKD Stage 5 Patients in a Phase 3 Study" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca&amp;name=Figure%201.jpg">
</div></span>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="bfbb1631-81fd-4440-a10a-fc1e6daadac1"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Paricalcitol Injection is available in multi-dose vials as follows:</p>
<table width="100%">
<col width="23%">
<col width="26%">
<col width="23%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="bottom"><p class="First"><span class="Bold">Unit of Sale</span></p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Total Content/ Concentration</span></p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Volume/Container</span></p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Each</span></p></td>
</tr>
<tr>
<td class="Botrule">
<p class="First"><span class="Bold">NDC 0409-1007-01</span></p>
<p>Carton of 25</p>
</td>
<td class="Botrule Toprule" align="center"><p class="First">2 mcg/mL<br>   </p></td>
<td class="Botrule Toprule" align="center"><p class="First">1 mL<br>  </p></td>
<td class="Botrule Toprule" align="center"><p class="First">NDC 0409-1007-11<br>   </p></td>
</tr>
<tr>
<td class="Botrule">
<p class="First"><span class="Bold">NDC 0409-1008-01</span></p>
<p>Carton of 25</p>
</td>
<td class="Botrule Toprule" align="center"><p class="First">5 mcg/mL<br>   </p></td>
<td class="Botrule Toprule" align="center"><p class="First">1 mL<br>   </p></td>
<td class="Botrule Toprule" align="center"><p class="First">NDC 0409-1008-11<br>   </p></td>
</tr>
<tr class="Last">
<td class="Botrule Toprule">
<p class="First"><span class="Bold">NDC 0409-1008-02</span></p>
<p>Carton of 25</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">10 mcg/2 mL</p>
<p>(5 mcg/mL)</p>
</td>
<td class="Botrule Toprule" align="center"><p class="First">2 mL<br>   </p></td>
<td class="Botrule Toprule" align="center"><p class="First">NDC 0409-1008-12<br>   </p></td>
</tr>
</tbody>
</table>
<p>Store under normal lighting conditions at 20° - 25°C (68° - 77°F) [see USP controlled room temperature]. Do not freeze. After breakage of the seal for first use the multi-dose vials are stable for up to 28 days when stored between 20° - 25°C (68° - 77°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ac7e4699-0516-44ef-b9ee-0ee81cd02bb5"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised: </p>
<dl>
<dt>•</dt>
<dd>of the most common adverse reactions with use of Paricalcitol Injection, which include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</dd>
<dt>•</dt>
<dd>to adhere to instructions regarding diet and phosphorus restriction.</dd>
<dt>•</dt>
<dd>to contact a health care provider if they develop symptoms of elevated calcium, (e.g. feeling tired, <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">difficulty thinking</span> clearly, loss of appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span>, increased urination and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>). </dd>
<dt>•</dt>
<dd>to return to their dialysis clinic/health care provider’s office for routine monitoring. More frequent monitoring is necessary during the initiation of therapy, following dose changes or when potentially interacting medications are started or discontinued. </dd>
<dt>•</dt>
<dd>to inform their health care provider of all medications, including prescription and nonprescription drugs, supplements, and herbal preparations they are taking and any change to their medical condition. Patients should also be advised to inform their health care provider prescribing a new medication that they are taking Paricalcitol Injection.</dd>
</dl>
<p>EN-3689</p>
<p>Hospira, Inc., Lake Forest, IL 60045 USA                                                                                <a name="id1999613666"></a><img alt="Hospira logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca&amp;name=Hospira%20logo.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="f30b7a40-c218-4cf4-b07c-831ab5734d4c"></a><a name="section-16"></a><p></p>
<h1>CA-3670</h1>
<div class="Figure">
<a name="id-763678857"></a><img alt="Carton NDC 0409-1007-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca&amp;name=Carton%20NDC%200409-1007-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="b30e390a-970b-4208-8531-e27f166f0656"></a><a name="section-17"></a><p></p>
<h1>CA-3671</h1>
<div class="Figure">
<a name="id-711185185"></a><img alt="Carton NDC 0409-1008-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca&amp;name=Carton%20NDC%200409-1008-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_6ed92b73-c01a-4be5-a4b4-ff86843ab0e1"></a><a name="section-18"></a><p></p>
<h1>CA-3672</h1>
<div class="Figure">
<a name="id459624920"></a><img alt="Carton NDC 0409-1008-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca&amp;name=Carton%20NDC%200409-1008-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PARICALCITOL 		
					</strong><br><span class="contentTableReg">paricalcitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-1008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PARICALCITOL</strong> (PARICALCITOL) </td>
<td class="formItem">PARICALCITOL</td>
<td class="formItem">5 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-1008-01</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-1008-11</td>
<td class="formItem">1 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0409-1008-02</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0409-1008-12</td>
<td class="formItem">2 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201657</td>
<td class="formItem">11/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PARICALCITOL 		
					</strong><br><span class="contentTableReg">paricalcitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-1007</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PARICALCITOL</strong> (PARICALCITOL) </td>
<td class="formItem">PARICALCITOL</td>
<td class="formItem">2 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-1007-01</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-1007-11</td>
<td class="formItem">1 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201657</td>
<td class="formItem">11/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f85817fb-ede9-4bbd-80ab-a1b67f09fa28</div>
<div>Set id: b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca</div>
<div>Version: 1</div>
<div>Effective Time: 20141024</div>
</div>
</div> <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
